http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27045436.html <p>NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=k0HElseLPxhaEdJbgr9XrTNTDmE47d9CgTT-QTyOqH6_cO2Psbp7lMsoW45fbkXnosRuO2fsmNFkai_DIDB37ki5lSPozK7h1MHbYpHCfA4-YprU5sogfaBB61GRXrNRMrc6LAFAaBiqAMgks_pPmi0THvF0lqP9dKWWcCJhUaODuu9N6rGpmn5owLfKKsR8dgSQsfDnxcDhaZNjPd5oy855kVZdKlObu5nxVfoTj93vKi2C97AUOCUMwd40LCkMNeziQjPiXHhz1HCwxzdahBer4g7WWOIc3YEloxjARBywxz5rg-JZumc0Zm95jx-f" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.</p> <p><strong><em>Presentation details:</em></strong><br/><strong>Format: </strong>Company presentation and 1 on 1 meetings<br/><strong>Date &amp; time:</strong> September 14th, 2026, at 11:30 AM ET<br/><strong>Webcast:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=P7Hs7A_UhXv2qR4gkkXBzNm8dBSMfEgmJhbplU1r-tHxGR6xeTb_mwwgG1hJUidrojR4y0om-R9SL8JHoCNE-69uZH-XymOr_63R7boiJCFsOZiDGN1zy5k5S7U2OETFj4CIGX49H8JKKCdqqcBb_y8POipcwGSlzEA2lu7KyHBlkNtZrRZN9oJqcW6QirZnrsFSk1ZFOXWDvpOU0ruMZrM_qCzSRiYa-O3P-QltQJo=" rel="nofollow" target="_blank">https://journey.ct.events/view/c18a40de-8b48-4807-b323-6fd60b6d73a8</a></p> <p>The Galectin management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright.</p> <p>The http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27045436.html Thu, 10 Sep 2026 08:00:00 -0400 GALT http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27045436.html <p>NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=k0HElseLPxhaEdJbgr9XrTNTDmE47d9CgTT-QTyOqH6_cO2Psbp7lMsoW45fbkXnosRuO2fsmNFkai_DIDB37ki5lSPozK7h1MHbYpHCfA4-YprU5sogfaBB61GRXrNRMrc6LAFAaBiqAMgks_pPmi0THvF0lqP9dKWWcCJhUaODuu9N6rGpmn5owLfKKsR8dgSQsfDnxcDhaZNjPd5oy855kVZdKlObu5nxVfoTj93vKi2C97AUOCUMwd40LCkMNeziQjPiXHhz1HCwxzdahBer4g7WWOIc3YEloxjARBywxz5rg-JZumc0Zm95jx-f" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.</p> <p><strong><em>Presentation details:</em></strong><br/><strong>Format: </strong>Company presentation and 1 on 1 meetings<br/><strong>Date &amp; time:</strong> September 14th, 2026, at 11:30 AM ET<br/><strong>Webcast:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=P7Hs7A_UhXv2qR4gkkXBzNm8dBSMfEgmJhbplU1r-tHxGR6xeTb_mwwgG1hJUidrojR4y0om-R9SL8JHoCNE-69uZH-XymOr_63R7boiJCFsOZiDGN1zy5k5S7U2OETFj4CIGX49H8JKKCdqqcBb_y8POipcwGSlzEA2lu7KyHBlkNtZrRZN9oJqcW6QirZnrsFSk1ZFOXWDvpOU0ruMZrM_qCzSRiYa-O3P-QltQJo=" rel="nofollow" target="_blank">https://journey.ct.events/view/c18a40de-8b48-4807-b323-6fd60b6d73a8</a></p> <p>The Galectin management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright.</p> <p>The http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+to+Present+at+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/27045436.html Thu, 10 Sep 2026 08:00:00 -0400 GALT http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html <p>NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=O5y8ONRe-4yeCy-UJZl7X8rsQUjCTEL-qr4JeYFYF9o2ApnXmVFsIw42MFa2WYqUTc1g-V3CA98ZRxNCF8P9BlHZOmrdWl5VRHzpazLIxWPc01a5f2pKaTwB1ruSg5JD" rel="nofollow" target="_blank">Galectin Therapeutics, Inc.</a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.</p> <p>“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Reports+June+30%2C+2026+Financial+Results+and+Provides+Business+Update%C2%A0/26924750.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 A.32868407 GALT O.01956176 O.20026344 O.22802303 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GALECTIN+THERAPEUTICS+++++For%3A+Aug+14/26924695.html si-local-file:///var/storage/secattach/20260814/26924695.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GALECTIN+THERAPEUTICS+++++For%3A+Aug+14/26924695.html Fri, 14 Aug 2026 07:56:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GALECTIN+THERAPEUTICS+++++For%3A+Aug+14/26924695.html si-local-file:///var/storage/secattach/20260814/26924695.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++GALECTIN+THERAPEUTICS+++++For%3A+Aug+14/26924695.html Fri, 14 Aug 2026 07:56:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+30/26924681.html si-local-file:///var/storage/secattach/20260814/26924681.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+30/26924681.html Fri, 14 Aug 2026 07:51:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+30/26924681.html si-local-file:///var/storage/secattach/20260814/26924681.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GALECTIN+THERAPEUTICS+++++For%3A+Jun+30/26924681.html Fri, 14 Aug 2026 07:51:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Uihlein+Richard+E/26862379.html si-local-file:///var/storage/secattach/20260804/26862379.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Uihlein+Richard+E/26862379.html Tue, 04 Aug 2026 08:30:00 -0400 GALT O.01956176 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Uihlein+Richard+E/26862379.html si-local-file:///var/storage/secattach/20260804/26862379.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++GALECTIN+THERAPEUTICS++++++++++++++++++Filed+by%3A+Uihlein+Richard+E/26862379.html Tue, 04 Aug 2026 08:30:00 -0400 GALT O.01956176 http://www.streetinsider.com/Equity+Offerings/Galectin+Therapeutics+converts+%24105.8M+in+debt+to+equity/26862069.html <p>Galectin Therapeutics Inc. (NASDAQ: GALT) announced that its chairman and largest stockholder, Richard E. Uihlein, converted approximately $105.8 million in outstanding debt into common stock, effective July 31, 2026.</p><p>The transaction eliminated $91.0 million in principal and approximately $14.8 million in accrued interest across five line of credit facilities. In exchange, the company issued 34,376,167 shares of common stock to Mr. Uihlein at a blended average conversion price of approximately $3.07 per share, based on pre-existing conversion rights under the applicable promissory notes.</p><p>Following the conversion, Galectin had 100,849,644 shares of common stock outstanding as of July 31, 2026.</p><p>The conversion covered notes http://www.streetinsider.com/Equity+Offerings/Galectin+Therapeutics+converts+%24105.8M+in+debt+to+equity/26862069.html Tue, 04 Aug 2026 08:04:36 -0400 GALT http://www.streetinsider.com/Corporate+News/Galectin+Therapeutics+converts+%24105.8M+in+debt+to+equity/26862069.html <p>Galectin Therapeutics Inc. (NASDAQ: GALT) announced that its chairman and largest stockholder, Richard E. Uihlein, converted approximately $105.8 million in outstanding debt into common stock, effective July 31, 2026.</p><p>The transaction eliminated $91.0 million in principal and approximately $14.8 million in accrued interest across five line of credit facilities. In exchange, the company issued 34,376,167 shares of common stock to Mr. Uihlein at a blended average conversion price of approximately $3.07 per share, based on pre-existing conversion rights under the applicable promissory notes.</p><p>Following the conversion, Galectin had 100,849,644 shares of common stock outstanding as of July 31, 2026.</p><p>The conversion covered notes http://www.streetinsider.com/Corporate+News/Galectin+Therapeutics+converts+%24105.8M+in+debt+to+equity/26862069.html Tue, 04 Aug 2026 08:04:36 -0400 GALT http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Conversion+of+%24105.8+Million+in+Debt+to+Equity%2C+Significantly+Strengthening+Balance+Sheet/26861841.html <p align="center"><em>Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock</em></p> <p align="center"><em>Transaction eliminates approximately $105.8 million in debt and increases market capitalization</em></p> <p>NORCROSS, Ga., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT) (&quot;Galectin&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and portal hypertension associated with MASH cirrhosis, today announced that Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, has converted all outstanding principal and accrued interest under five of the Company’s http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Conversion+of+%24105.8+Million+in+Debt+to+Equity%2C+Significantly+Strengthening+Balance+Sheet/26861841.html Tue, 04 Aug 2026 08:00:00 -0400 GALT O.01956176 http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Conversion+of+%24105.8+Million+in+Debt+to+Equity%2C+Significantly+Strengthening+Balance+Sheet/26861841.html <p align="center"><em>Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock</em></p> <p align="center"><em>Transaction eliminates approximately $105.8 million in debt and increases market capitalization</em></p> <p>NORCROSS, Ga., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT) (&quot;Galectin&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and portal hypertension associated with MASH cirrhosis, today announced that Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, has converted all outstanding principal and accrued interest under five of the Company’s http://www.streetinsider.com/Press+Releases/Galectin+Therapeutics+Announces+Conversion+of+%24105.8+Million+in+Debt+to+Equity%2C+Significantly+Strengthening+Balance+Sheet/26861841.html Tue, 04 Aug 2026 08:00:00 -0400 GALT O.01956176 http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Announces+Conversion+of+%24105.8+Million+in+Debt+to+Equity%2C+Significantly+Strengthening+Balance+Sheet/26861841.html <p align="center"><em>Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock</em></p> <p align="center"><em>Transaction eliminates approximately $105.8 million in debt and increases market capitalization</em></p> <p>NORCROSS, Ga., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT) (&quot;Galectin&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and portal hypertension associated with MASH cirrhosis, today announced that Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, has converted all outstanding principal and accrued interest under five of the Company’s http://www.streetinsider.com/Globe+Newswire/Galectin+Therapeutics+Announces+Conversion+of+%24105.8+Million+in+Debt+to+Equity%2C+Significantly+Strengthening+Balance+Sheet/26861841.html Tue, 04 Aug 2026 08:00:00 -0400 GALT O.01956176